Inhibikase Therapeutics (IKT) Insider & Congress Trades

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Mar 31, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about IKT filings

Are insiders buying or selling Inhibikase Therapeutics Inc (IKT) stock?

Neither. Inhibikase Therapeutics Inc (IKT) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IKT recently?

None. No member of Congress disclosed a IKT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IKT smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

14 funds hold a position.

Questions about IKT filings

Are insiders buying or selling Inhibikase Therapeutics Inc (IKT) stock?

Neither. Inhibikase Therapeutics Inc (IKT) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IKT recently?

None. No member of Congress disclosed a IKT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IKT smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 27, 2026

Earnings came in 12.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 27, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.11+12.00% beat

-$0.13 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$0.13

-$0.16 to -$0.11

Revenue expected

$187.5K

8 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.01

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 27, 2026	-$0.11est. -$0.13	+12.00%beat	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 11, 2026	-$0.11est. -$0.09	-$0.02miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 12, 2026	-$0.10est. -$0.09	-$0.01miss	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Mar 26, 2026	-$0.09est. -$0.12	+25.00%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 14, 2025	-$0.13est. -$0.13	+0.00%in line	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 14, 2025	-$0.11est. -$0.08	-$0.03miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 14, 2025	-$0.15est. -$0.09	-$0.06miss	$0.00SEC filing	No year-ago quarter
Dec 31, 2024Reported Mar 26, 2025	-$0.17est. -$0.09	-$0.09miss	$0.00 · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.65
High: $1.65
Low: $1.53
Prev close: $1.68
52-wk high: $2.61
52-wk low: $1.40
Mkt cap: $214.6M
ROE: -52.9%
Beta: 0.94
P/S: 10.4x
P/B: 1.2x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $215M

Valuation

P/S10.39
P/B1.20

Quality

Operating margin0.0%
ROE-52.9%
ROA-33.8%

Growth

Beta0.94

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

45balanced

20D volatility

87%annualized

52-week range

$1.55

$1.40$2.61

20D support

$1.43recent floor

20D resistance

$1.87recent ceiling

Returns

5D +4.7%20D -11.9%60D -35.1%

Price vs moving averages

SMA20 -3.7%SMA50 -20.5%SMA200 -19.7%

Volume pace

1.03xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Oct 27, 2026

-$0.11est. -$0.13

+12.00%

$0.00Yahoo Finance

No year-ago quarter

Jun 30, 2026Aug 11, 2026

-$0.11est. -$0.09

-$0.02

$0.00SEC filing

No year-ago quarter

Mar 31, 2026May 12, 2026

-$0.10est. -$0.09

-$0.01

$0.00SEC filing

No year-ago quarter

Dec 31, 2025Mar 26, 2026

-$0.09est. -$0.12

+25.00%

$0.00Yahoo Finance

No year-ago quarter

Sep 30, 2025Nov 14, 2025

-$0.13est. -$0.13

+0.00%

$0.00SEC filing

No year-ago quarter

Jun 30, 2025Aug 14, 2025

-$0.11est. -$0.08

-$0.03

$0.00SEC filing

No year-ago quarter

Mar 31, 2025May 14, 2025

-$0.15est. -$0.09

-$0.06

$0.00SEC filing

No year-ago quarter

Dec 31, 2024Mar 26, 2025

-$0.17est. -$0.09

-$0.09

$0.00 · FYSEC filing

No year-ago quarter

Inhibikase Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about IKT filings

Questions about IKT filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 12.0% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Inhibikase Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about IKT filings

Questions about IKT filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 12.0% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Inhibikase Therapeutics Inc

Overview

Questions about IKT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Inhibikase Therapeutics Inc

Overview

Questions about IKT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.